Literature DB >> 160445

Interactions between central monoaminergic systems: dopamine-serotonin.

G Roccatagliata, C Albano, L Cocito, M Maffini.   

Abstract

Concentration of dopamine and serotonin metabolites (HVA and 5-HIAA) in the CSF was evaluated before and after pharmacological treatment in 19 patients with different neuropsychiatric diseases. In every case a reciprocal modification of the two metabolites occurred after treatment. The result supports the hypothesis of a functional balance between the monoaminergic systems in the central nervous system.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 160445      PMCID： PMC490433          DOI： 10.1136/jnnp.42.12.1159

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  11 in total

1.  Neurohumoral interactions and basal ganglia function and dysfunction.

Authors:  O Hornykiewicz
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1976

2.  [Choreic dyskinesia and GABA - pharmaco-clinical approach. Preliminary note].

Authors:  G Roccatagliata; C Albano; G Besio; E M Ivaldi
Journal:  Schweiz Arch Neurol Neurochir Psychiatr       Date:  1978

3.  Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour.

Authors:  A R Green; M B Youdim; D G Grahame-Smith
Journal:  Neuropharmacology       Date:  1976-03       Impact factor: 5.250

4.  Influence of GABA and GABA-like drugs on monoaminergic mechanisms.

Authors:  A Carlsson; B Biswas; M Lindqvist
Journal:  Adv Biochem Psychopharmacol       Date:  1977

5.  Decrease in homovanillic acid as evidence for dopamine receptor stimulation by apomorphine in the neostriatum of the rat.

Authors:  B E Roos
Journal:  J Pharm Pharmacol       Date:  1969-04       Impact factor: 3.765

6.  ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors.

Authors:  H Corrodi; L O Farnebo; K Fuxe; B Hamberger; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1972-11       Impact factor: 4.432

7.  Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenylglycol in cerebrospinal fluid.

Authors:  J Korf; H M van Praag; J B Sebens
Journal:  Biochem Pharmacol       Date:  1971-03       Impact factor: 5.858

8.  Fluorometric determination of homovanillic acid in biological material after isolation on Sephadex G-10.

Authors:  J Korf; S Ottema; I van der Veen
Journal:  Anal Biochem       Date:  1971-03       Impact factor: 3.365

9.  Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa.

Authors:  D J Heal; A R Green; D J Boullin; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1976-09-29       Impact factor: 4.530

10.  Classification of mental disorders.

Authors:  E STENGEL
Journal:  Bull World Health Organ       Date:  1959       Impact factor: 9.408
View more
  4 in total

Review 1.  Biochemical assessment of antidepressive drugs.

Authors:  K Ghose
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

2.  Analysis of equine cisterna magna cerebrospinal fluid for the presence of some monoamine neurotransmitters and transmitter metabolites.

Authors:  D M Vaughn; G B Smyth; W L Whitmer; C Satjawatcharaphong
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

3.  Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.

Authors:  Sumie Leung; Rodney J Croft; Valérie Guille; Kirsty Scholes; Barry V O'Neill; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

4.  Different gradients for neurotransmitter metabolites and protein in horse cerebrospinal fluid.

Authors:  D M Vaughn; G B Smyth
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.